FNA smears as a potential source of DNA for targeted next‐generation sequencing of lung adenocarcinomas
Open Access
- 16 February 2016
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 124 (6) , 406-414
Abstract
BACKGROUND: Diff‐Quik–stained fine‐needle aspiration (FNA) smears and touch preparations from biopsies represent alternative specimens for molecular testing when cell block or biopsy material is insufficient. This study describes the use of these samples for targeted next‐generation sequencing (NGS) of primary and metastatic lung adenocarcinoma and reports the DNA quality and success rates of FNA smears versus other specimens from 1 year of clinical use.METHODS: A validation set of 10 slides from 9 patients with prior clinical epidermal growth factor receptor (EGFR) Sanger sequencing and KRAS pyrosequencing (5 KRAS‐positive/EGFR‐negative and 4 KRAS‐negative/EGFR‐negative) underwent DNA extraction, quality assessment, and targeted NGS. Subsequently, lung adenocarcinoma specimens submitted for NGS solid tumor mutation panel testing in 1 calendar year (60 biopsies, 57 resections, 33 FNA cell blocks, 12 FNA smears, and 10 body fluid cell blocks) were reviewed for specimen adequacy, sequencing success, and DNA quality.RESULTS: All 10 validation samples met the DNA quality threshold (delta Ct threshold < 8; range, –2.2 to 4.9) and yielded 0.5 to 22 μg of DNA. The KRAS and EGFR mutation status from FNA smears according to NGS was concordant with previous clinical testing for all 10 samples. In the 1‐year review, FNA smears were 100% successful, and this suggested a performance equivalent to or better than the performance of established specimen types, including FNA cell blocks. DNA quality according to ΔCt was significantly better with FNA smears versus biopsies, resections, and FNA cell blocks.CONCLUSIONS: FNA smears of lung adenocarcinomas are high‐quality alternative specimens for a targeted NGS panel with a high success rate in clinical practice. Cancer Cytopathol 2016;124:406–14. © 2016 American Cancer Society.Keywords
Funding Information
- Department of Pathology and Laboratory Medicine of the University of North Carolina
- University Cancer Research Fund
- University of North Carolina Clinical Translational Science Award (National Institutes of Health UL1TR001111)
- UNC Health Care
- National Institutes of Health (U01HG006487, 1U19HD077632-01, UL1TR001111)
This publication has 27 references indexed in Scilit:
- Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencingCancer Cytopathology, 2014
- Next Generation Sequencing Improves the Accuracy of KRAS Mutation Analysis in Endoscopic Ultrasound Fine Needle Aspiration Pancreatic LesionsPLOS ONE, 2014
- Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing PanelPLOS ONE, 2013
- Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lungCancer Cytopathology, 2013
- Impact of Different Methodologies on the Detection of Point Mutations in Routine Air-dried Fine Needle Aspiration (FNA) SmearsHormone and Metabolic Research, 2013
- Molecular Diagnostics of Melanoma Fine-Needle AspiratesAmerican Journal of Clinical Pathology, 2012
- BRAF V600E Mutation Analysis from May-Grünwald Giemsa-Stained Cytological Samples as an Adjunct in Identification of High-Risk Papillary Thyroid CarcinomaEndocrine Pathology, 2011
- EGFR and KRAS mutations in lung carcinomaCancer Cytopathology, 2011
- Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCRPLOS ONE, 2011
- Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular DiagnosisJournal of Thoracic Oncology, 2007